NRG1 and prostate cancer: A role of CAF-derived Neuregulin 1 (NRG1) in drug resistance was also reported by Zhang et al, who demonstrated that this soluble molecule conferred anti-androgen resistance in prostate cancer, again through HER3 activation, and that patients with increased tumor NRG1 activity showed a lower response to second-generation antiandrogen therapy [73].